‘The Evolution of the Biopharma Industry: from 1987 to 2022’
On November 29, Karen Bernstein, the Co-founder and Chairman of BioCentury Inc., the leading provider of analytical insight and data for the biopharmaceutical industry, will host a ‘Talks at the Square’ at BioInnovation Institute (BII).
In a fireside chat with Bobby Soni, Chief Business Officer at BII, Karen will delve into the key learnings obtained during 35 years of working in the biopharmaceutical industry. Through concrete examples of both ups and downs in the sector, she will take the audience on a trip down memory lane to 1987 when she started working in the industry. Based on her experiences, she will share her personal reflections on how and why the industry has evolved over time from being heavily underexposed to receiving huge attention globally as an absolute cornerstone in tackling some of the world’s grand societal challenges related to both human and planetary health.
Karen will also touch upon market cycles and how different historical phases of market growth and decline have been essential in determining the overall development in the biopharmaceutical industry. This will lead her to try to answer one of the big questions that many entrepreneurs are wondering about: where is the industry heading?
Program of the day
15.30 Doors open
16.00 Introduction to BII and the subject of the day: Bobby Soni, CBO at BII
16.10 Fireside chat w. Karen Bernstein & Bobby Soni: ‘The Evolution of the Biopharma Industry: from 1987 to 2022’
17.00 Informal networking and closing reception
Please note that the event has free admittance with 70 tickets available. Please sign up quickly to secure your seat.
If you have registered for the event but cannot attend, please email firstname.lastname@example.org.
About Karen Bernstein:
Dr. Karen Bernstein is an entrepreneur who co-founded, co-owns, and is chairman of BioCentury Inc., the leading provider of analytical insight and data for the biopharmaceutical industry. She has worked in the biopharma space since 1987 and currently sits on the boards of several companies and academic institutions, including Ovid Therapeutics Inc., Codiak Biosciences Inc., the board of overseers of Scripps Research, and the board of trustees of Keck Graduate Institute.